CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more
CellaVision AB - Asset Resilience Ratio
CellaVision AB (CEVI) has an Asset Resilience Ratio of -0.58% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2022)
This chart shows how CellaVision AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CellaVision AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr-5.15 Million | -0.58% |
| Total Liquid Assets | Skr-5.15 Million | -0.58% |
Asset Resilience Insights
- Limited Liquidity: CellaVision AB maintains only -0.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
CellaVision AB Industry Peers by Asset Resilience Ratio
Compare CellaVision AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for CellaVision AB (2012–2022)
The table below shows the annual Asset Resilience Ratio data for CellaVision AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.58% | Skr-5.15 Million | Skr891.75 Million | +2.06pp |
| 2021-12-31 | -2.64% | Skr-21.79 Million | Skr825.21 Million | -0.06pp |
| 2020-12-31 | -2.58% | Skr-17.25 Million | Skr668.02 Million | +0.21pp |
| 2019-12-31 | -2.79% | Skr-17.93 Million | Skr641.71 Million | -16.83pp |
| 2013-12-31 | 14.03% | Skr26.47 Million | Skr188.57 Million | +13.86pp |
| 2012-12-31 | 0.18% | Skr318.00K | Skr178.56 Million | -- |